硫酸氢氯吡格雷联合依诺肝素钠治疗非ST段抬高型心肌梗死的疗效观察

The efficacy of clopidogrel hydrogen sulphate combined with enoxaparin sodium for non-ST segment elevation myocardial infarction

目的 探讨硫酸氢氯吡格雷（波立维）联合依诺肝素钠（克赛）治疗非ST段抬高型心肌梗死（non-ST-segment elevation myocardial infarction,NSTEMI）的临床疗效.方法 将173例NSTEMI随机分为治疗组（87例）和对照组（86例）,对照组用克赛皮下注射0.4 ml,每12小时一次,安慰剂口服,一天一次,共7天；治疗组在对照组的基础上加用波立维75 mg口服,一天一次,共7天.结果 治疗组疗效明显优于对照组,治疗组总有效率91.95％,对照组总有效率83.72％,两组在总有效率上差异有统计学意义（P＜0.05）.结论 治疗组比对照组起效快、作用强、效果好,能迅速缓解心绞痛发作,保护心脏功能,减少并发症及降低病死率.

Objective To investigate the clinical efficacy of clopidogrel hydrogen sulphate （Plavix） in combination with enoxaparin sodium （Clexane） in the treatment of non-ST segment elevation myocardial infarction （NSTEMI）.Methods 173 patients with NSTEMI were randomly divided into a study group （n =87） and a control group （n=86）.The control received subcutaneous injection of 0.4 ml Clexane once 12 hours and oral placebo once daily for one week; while the study group received oral Plavix of 75mg once daily for one week in addition to Clexane injections and plcebo.Results The study group was obviously superior to the control group in the efficacy; the total effectiveness rate was 91.95% in the study group and 83.72% in the control group,with a statistical difference （P〈0.05）.Conclusions The combination therapy in the study group has a quicker onset,stronger action,and a better effect than the control group.It can rapidly relieve angina attack,protect heart function,and reduce the rates of complications and mortality.